Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 955

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 955
---
--|:---------------------------------------|:--|----:|:--|:--|:--|:-----|:--|----:|:--|:--|
| Research and development       | ​ | ​ | ​                                      | $ |  86 | ​ | ​ | ​ | ​    | $ |  84 | ​ | ​ |
| General and administrative     | ​ | ​ | ​                                      | ​ | 154 | ​ | ​ | ​ | ​    | ​ | 145 | ​ | ​ |
| Total stock-based compensation | ​ | ​ | ​                                      | $ | 240 | ​ | ​ | ​ | ​    | $ | 229 | ​ | ​ |

F-129

TABLE OF CONTENTS

Tvardi Therapeutics, Inc. Notes to CONDENSED Financial Statements
(Unaudited) 11. Income Taxes For the three and nine months ended September 30, 2024 and 2023, there was no current or deferred income tax expense or benefit due to the Company’s current year losses and full valuation allowance. As of September 30, 2024, the Company evaluated all available evidence and concluded that a valuation allowance is still required against its net deferred tax assets because it is more likely than not they will not be realized in the foreseeable future.. 12. Net Loss Per Share Basis and diluted net loss per share attributable to common stockholders was calculated as follows (dollar amounts in thousands):

| ​                                                                         
 ​                                                                         
 Numerator:                                                                | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | For the Nine Months EndedSeptember 30, 
 2024                                   
 ​                                      | ​ |          ​ | ​ | ​ 
 ​ | ​ 
 ​ | 2023 
 ​    | ​ |          ​ | ​ | ​ 
 ​ 
 ​ |
|:--------------------------------------------------------------------------|:--|:--|:---------------------------------------|:--|-----------:|:--|:--|:--|:-----|:--|-----------:|:--|:--|
| Net loss attributable to common stockholders                              | ​ | ​ | ​                                      | $ |    -16,690 | ​ | ​ | ​ | ​    | $ |    -12,996 | ​ | ​ |
| Denominator:                                                              | ​ | ​ | ​                                      | ​ |          ​ | ​ | ​ | ​ | ​    | ​ |          ​ | ​ | ​ |
| Weighted-average common shares